Ben Pope

Ben is pursuing a lifelong mission to cure diseases that debilitated members of his family. He is Founder and CEO of MelliCell, a biotechnology company based in Boston pioneering an oral pill for obesity, autism, and neurodegeneration that targets a shared root cause. Before starting MelliCell, Ben received his PhD in Biology with a Ruth L. Kirschstein fellowship and cross-trained in Engineering as a Good Ventures Postdoctoral Fellow at Harvard. Ben’s work has been published in over 21 scientific articles including Nature and Cell and he is the inventor of 5 patents including MelliCell’s core technology. With his leadership, MelliCell has attracted a renowned team of experts, executed agreements with the leading pharma companies, and completed milestones with millions in private capital and multiple federal awards. MelliCell’s first drug candidate will be reaching patients next year in a Phase 1a/b clinical trial.